clinical trial · NCT03033303
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
NeuroblastomaHu3F8GM-CSFIsotretinoin
brief summary
The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side effects.
started
Jan 23, 2017
primary completion
Sep 29, 2025
completion
Sep 29, 2025
last updated
Oct 7, 2025
official title
Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol